Syndax Pharmaceuticals (SNDX) Income from Continuing Operations: 2015-2020
Historic Income from Continuing Operations for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' Income from Continuing Operations fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
- Syndax Pharmaceuticals' Income from Continuing Operations amounted to -$19.9 million in Q4 2020, which was down 0.04% from -$19.9 million recorded in Q3 2020.
- Syndax Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$8.4 million for Q2 2016, and its period low was -$19.9 million during Q4 2020.
- Over the past 3 years, Syndax Pharmaceuticals' median Income from Continuing Operations value was -$17.2 million (recorded in 2018), while the average stood at -$17.1 million.
- Per our database at Business Quant, Syndax Pharmaceuticals' Income from Continuing Operations slumped by 145.93% in 2016 and then climbed by 26.52% in 2019.
- Quarterly analysis of 5 years shows Syndax Pharmaceuticals' Income from Continuing Operations stood at -$10.9 million in 2016, then slumped by 74.99% to -$19.0 million in 2017, then fell by 1.61% to -$19.3 million in 2018, then grew by 26.52% to -$14.2 million in 2019, then slumped by 39.81% to -$19.9 million in 2020.
- Its last three reported values are -$19.9 million in Q4 2020, -$19.9 million for Q3 2020, and -$16.6 million during Q2 2020.